Biohaven (BHVN) Stock Price

Biohaven Price

NYSE·CLOSED
13.50USD-0.32 (-2.34 %)
Market closed

The consensus 12-month price target for Biohaven is 15.30 USD, about 13.3% above where the stock trades today. Of 23 analysts, 17 rate the stock a buy — an overall Buy consensus. The stock trades about 73% above its 52-week low.

Biohaven stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Biohaven over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Biohaven stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Biohaven's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Biohaven Stock Price History
DateBiohaven Price
7/31/202613.50 USD
7/30/202613.82 USD
7/29/202613.59 USD
7/27/202614.43 USD
7/23/202614.65 USD
7/22/202614.75 USD
7/21/202615.51 USD
7/20/202614.86 USD
7/17/202615.44 USD
7/16/202614.17 USD
7/15/202614.86 USD
7/14/202614.94 USD
7/13/202615.31 USD
7/10/202615.55 USD
7/9/202616.79 USD
7/8/202615.44 USD
7/7/202615.55 USD
7/6/202616.35 USD
7/2/202615.96 USD
7/1/202615.76 USD
6/30/202614.88 USD
6/29/202614.81 USD
6/26/202615.83 USD
6/25/202615.34 USD
6/24/202614.96 USD
6/23/202614.78 USD
6/22/202615.43 USD
6/18/202613.34 USD
6/17/202613.89 USD
6/16/202611.92 USD
6/15/202611.96 USD
6/12/202611.85 USD
6/11/202611.19 USD
6/10/202611.66 USD
6/9/202611.09 USD
6/8/202611.12 USD
6/5/202611.06 USD
6/4/202611.41 USD
6/3/202610.65 USD
6/2/202610.37 USD
6/1/202611.03 USD
5/29/202610.96 USD
5/28/202610.65 USD
5/27/202610.88 USD
5/26/202610.16 USD
5/22/20269.67 USD
5/21/20269.40 USD
5/20/20268.85 USD
5/19/20268.39 USD
5/18/20268.49 USD
5/15/20268.76 USD
5/14/20269.02 USD
5/13/20269.03 USD
5/12/20269.20 USD
5/11/20269.08 USD
5/8/20269.86 USD
5/7/20269.74 USD
5/6/202610.04 USD
5/5/20269.71 USD
5/4/202610.14 USD
5/1/20269.63 USD
4/30/20269.59 USD
4/29/20269.20 USD
4/28/20269.61 USD
4/27/20269.59 USD
4/24/20269.88 USD
4/23/202610.52 USD
4/22/202610.68 USD
4/21/202610.19 USD
4/20/202610.82 USD
4/17/202610.98 USD
4/16/202610.01 USD
4/15/202610.37 USD
4/14/202610.44 USD
4/13/202610.12 USD
4/10/20269.17 USD
4/9/20269.39 USD
4/8/20269.38 USD
4/7/20269.26 USD
4/6/20269.15 USD
4/2/20269.80 USD
4/1/20269.62 USD
3/31/20268.46 USD
3/30/20268.09 USD
3/27/20268.37 USD
3/26/20268.92 USD
3/25/20268.61 USD
3/24/20268.39 USD
3/23/20268.74 USD
3/20/20268.93 USD
3/19/20268.96 USD
3/18/20269.09 USD
3/17/20269.53 USD
3/16/20269.64 USD
3/13/20269.58 USD
3/12/20269.91 USD
3/11/202610.46 USD
3/10/202610.27 USD
3/9/202610.21 USD
3/6/20269.92 USD
3/5/202610.31 USD
3/4/202610.61 USD
3/3/202610.67 USD
3/2/202611.81 USD
2/27/202611.52 USD
2/26/202611.15 USD
2/25/202611.51 USD
2/24/202611.86 USD
2/23/202611.58 USD
2/20/202611.23 USD
2/19/202611.39 USD
2/18/202611.54 USD
2/17/202611.48 USD
2/13/202611.36 USD
2/12/202611.50 USD
2/11/202611.78 USD
2/10/202612.20 USD
2/9/202612.78 USD
2/6/202611.60 USD
2/5/202610.76 USD
2/4/202610.99 USD
2/3/202611.39 USD
2/2/202611.75 USD
1/30/202611.83 USD
1/29/202612.10 USD
1/28/202612.18 USD
1/27/202612.67 USD
1/26/202612.74 USD
1/23/202613.51 USD
1/22/202613.76 USD
1/21/202612.87 USD
1/20/202612.68 USD
1/16/202613.14 USD
1/15/202611.92 USD
1/14/202611.70 USD
1/13/202610.97 USD
1/12/202611.84 USD
1/9/202611.11 USD
1/8/202611.36 USD
1/7/202611.74 USD
1/6/20269.62 USD
1/5/20269.93 USD
1/2/202610.84 USD
12/31/202511.29 USD
12/30/202511.64 USD
12/29/202511.54 USD
12/26/202511.15 USD
12/24/202510.81 USD
12/23/202510.50 USD
12/22/202511.00 USD
12/19/202510.85 USD
12/18/202511.13 USD
12/17/202510.87 USD
12/16/202511.03 USD
12/15/202511.28 USD
12/12/202511.53 USD
12/11/202511.44 USD
12/10/202510.60 USD
12/9/202510.48 USD
12/8/202510.54 USD
12/5/20259.55 USD
12/4/20259.61 USD
12/3/20259.12 USD
12/2/20258.83 USD
12/1/20259.32 USD
11/28/202510.03 USD
11/26/20259.48 USD
11/25/20259.41 USD
11/24/20259.68 USD
11/21/20259.69 USD
11/20/20259.63 USD
11/19/20259.46 USD
11/18/20259.45 USD
11/17/20258.27 USD
11/14/20258.30 USD
11/13/20258.08 USD
11/12/20257.95 USD
11/11/20258.52 USD
11/10/20257.79 USD
11/7/20258.26 USD
11/6/20258.53 USD
11/5/20258.34 USD
11/4/20258.34 USD
11/3/20258.88 USD
10/31/202510.28 USD
10/30/202510.40 USD
10/29/202510.83 USD
10/28/202510.28 USD
10/27/202510.40 USD
10/24/20259.92 USD
10/23/20259.74 USD
10/22/20259.85 USD
10/21/202510.60 USD
10/20/202510.49 USD
10/17/20259.54 USD
10/16/20259.85 USD
10/15/202510.38 USD
10/14/20259.96 USD
10/13/20259.15 USD
10/10/20259.45 USD
10/9/202510.30 USD
10/8/20259.17 USD
10/7/20258.98 USD
10/6/20259.49 USD
10/3/20259.45 USD
10/2/20259.27 USD
10/1/20258.86 USD
9/30/20258.97 USD
9/29/20258.76 USD
9/26/20258.97 USD
9/25/20258.26 USD
9/24/20258.21 USD
9/23/20258.47 USD
9/22/20258.88 USD
9/19/20258.56 USD
9/18/20259.28 USD
9/17/20258.79 USD
9/16/20258.06 USD
9/15/20258.21 USD
9/12/20258.33 USD
9/11/20258.41 USD
9/10/20258.38 USD
9/9/20258.66 USD
9/8/20258.66 USD
9/5/20259.49 USD
9/4/20259.61 USD
9/3/20259.69 USD
9/2/20259.50 USD
8/29/20259.20 USD
8/28/20259.28 USD
8/27/20259.33 USD
8/26/20259.40 USD
8/25/20258.93 USD
8/22/20259.33 USD
8/21/20258.78 USD
8/20/20258.79 USD
8/19/20259.12 USD
8/18/20259.57 USD
8/15/20259.39 USD
8/14/20258.51 USD
8/13/20258.60 USD
8/12/20258.05 USD
8/11/20258.02 USD
8/8/20258.81 USD
8/7/20259.11 USD
8/6/20259.00 USD
8/5/20259.11 USD
Access this data via the Eulerpool API
Get Free API Key

Biohaven Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
0.00 USD
-436.05 M USD
-408.17 M USD
Jan 1, 2024
0.00 USD
-885.11 M USD
-846.42 M USD
Jan 1, 2025
0.00 USD
-745.38 M USD
-738.82 M USD
Jan 1, 2026 (e)
2.45 M USD
-465.25 M USD
-272.77 M USD
Jan 1, 2027 (e)
23.10 M USD
-398.00 M USD
-216.46 M USD
Jan 1, 2028 (e)
106.26 M USD
-309.85 M USD
-178.13 M USD
Jan 1, 2029 (e)
350.90 M USD
-180.11 M USD
-130.30 M USD
Jan 1, 2030 (e)
800.26 M USD
222.55 M USD
31.22 M USD

Biohaven Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 4, 2026, 11:45 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
––––––462.00––––2.0023.00106.00350.00800.00
––––––––––––1,050.00360.87230.19128.57
––––––80.09––––-200.00-17.39-3.77-1.14-0.50
-4.00-4.00-4.00-4.00-4.00-4.00370.00-1.00-3.00-3.00-4.00-4.00-4.00-4.00-4.00-4.00
-9.00-60.00–-224.00-479.00-114.00-218.00-567.00-436.00-885.00-745.00-465.00-398.00-309.00-180.00222.00
––––––-47.19––––-23,250.00-1,730.43-291.51-51.4327.75
-10.00-63.00–-240.00-528.00-118.00-213.00-570.00-408.00-846.00-738.00-272.00-216.00-178.00-130.0031.00
900.00530.00––120.00-77.6580.51167.61-28.42107.35-12.77-63.14-20.59-17.59-26.97-123.85
24.3324.3336.3639.1952.4548.4939.3760.8679.93101.06120.19120.19120.19120.19120.19120.19
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Biohaven generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Biohaven retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Biohaven's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Biohaven has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Biohaven's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Biohaven stock margins

The Biohaven margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biohaven. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biohaven.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
80.18 %
-47.33 %
-46.23 %
Jan 1, 2022
80.18 %
- %
- %
Jan 1, 2023
80.18 %
- %
- %
Jan 1, 2024
80.18 %
- %
- %
Jan 1, 2025
80.18 %
- %
- %
Jan 1, 2026 (e)
80.18 %
-18,979.70 %
-11,127.70 %
Jan 1, 2027 (e)
80.18 %
-1,723.24 %
-937.23 %
Jan 1, 2028 (e)
80.18 %
-291.59 %
-167.64 %

Biohaven Stock Revenue, EBIT, Earnings per Share

The Biohaven earnings per share therefore indicates how much revenue Biohaven has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
11.75 USD
-5.56 USD
-5.43 USD
Jan 1, 2022
0.00 USD
-9.33 USD
-9.37 USD
Jan 1, 2023
0.00 USD
-5.46 USD
-5.11 USD
Jan 1, 2024
0.00 USD
-8.76 USD
-8.38 USD
Jan 1, 2025
0.00 USD
-6.20 USD
-6.15 USD
Jan 1, 2026 (e)
0.03 USD
-3.87 USD
-2.99 USD
Jan 1, 2027 (e)
0.25 USD
-3.31 USD
-2.37 USD
Jan 1, 2028 (e)
1.16 USD
-2.58 USD
-1.95 USD

Biohaven business model & stock analysis

Biohaven Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Biohaven Employees
Details
Date
Biohaven Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Biohaven Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Biohaven historical P/E ratio, EBIT multiple, and P/S ratio

Biohaven annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Biohaven shares outstanding

The number of shares of Biohaven was 120.19 M in 2025. This indicates how many shares Biohaven is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
39.37 M Stocks
Jan 1, 2022
60.86 M Stocks
Jan 1, 2023
79.93 M Stocks
Jan 1, 2024
101.06 M Stocks
Jan 1, 2025
120.19 M Stocks
Jan 1, 2026 (e)
120.19 M Stocks
Jan 1, 2027 (e)
120.19 M Stocks
Jan 1, 2028 (e)
120.19 M Stocks

Current Biohaven forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
73.91 % (17)
Hold
26.09 % (6)
Sell
0.00 % (0)
12M Price Target
15.30
Last Price
13.50
Currency
USD
12M Return Potential
13.33 %
LTM Return
0 %

Biohaven Analyst Rating Actions

DateFirmActionRatingReliability
6/29/2026
B of A Securities
B of A Securities
DowngradeNeutralUnderperform70
5/26/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedNeutral–
5/13/2026
Morgan Stanley
Morgan Stanley
MaintainedOverweight60
5/5/2026
RBC Capital
RBC Capital
MaintainedOutperform52
4/2/2026
Citigroup
Citigroup
MaintainedBuy48
3/11/2026
TD Cowen
TD Cowen
MaintainedBuy60
3/4/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedNeutral–
3/3/2026
RBC Capital
RBC Capital
MaintainedOutperform52
1/21/2026
RBC Capital
RBC Capital
UpgradeSector PerformOutperform52
1/6/2026
Morgan Stanley
Morgan Stanley
MaintainedOverweight60

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Biohaven Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/10/2026-0.75USD-546,169.00USD-2026 Q2
5/11/2026-0.84USD-428,400.00USD-2026 Q1
3/19/2026-1.32USD-0.00USD-2025 Q4
8/3/2023-1.26USD-0.00USD-2023 Q2
5/8/2023-1.25USD-0.00USD-2023 Q1
2/23/2023-1.45USD-0.00USD-2022 Q4
11/9/2022-2.39USD-0.00USD-2022 Q3
8/5/2022-2.63USD-215.29 MUSD-2022 Q2
5/10/2022-2.58USD-183.83 MUSD-2022 Q1
2/25/2022-2.08USD-176.29 MUSD-2021 Q4

EESG©

Eulerpool ESG Scorecard© for the Biohaven stock

58/100
29
Environment
86
Social
61
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees58
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Biohaven shareholder structure

% Name
19.21932%
JANUS HENDERSON GROUP PLC
JANUS HENDERSON GROUP PLC
12.30064%
BLACKROCK, INC.
BLACKROCK, INC.
11.27530%
SUVRETTA CAPITAL MANAGEMENT, LLC
SUVRETTA CAPITAL MANAGEMENT, LLC
10.89600%
STIFEL FINANCIAL CORP
STIFEL FINANCIAL CORP
7.25473%
STATE STREET CORP
STATE STREET CORP
6.85049%
INFINITUM ASSET MANAGEMENT, LLC
INFINITUM ASSET MANAGEMENT, LLC
...

Biohaven Beneficial Ownership Filings (SEC 13D/G)

Free Float
82.2%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
12.00%
2
2
SEC ↗
11.70%
JANUS HENDERSON GROUP PLC
JANUS HENDERSON GROUP PLC
SEC ↗
9.40%
95-1411037
95-1411037
SEC ↗
8.50%
John W. Childs
John W. Childs
SEC ↗
7.90%
Capital International Investors **
Capital International Investors **
SEC ↗
7.80%
SUVRETTA CAPITAL MANAGEMENT, LLC
SUVRETTA CAPITAL MANAGEMENT, LLC
SEC ↗
6.74%
STATE STREET CORPORATION
STATE STREET CORPORATION
SEC ↗
6.10%
(1) BlackRock, Inc.
(1) BlackRock, Inc.
SEC ↗
5.80%
Vivo Capital VIII, LLC
Vivo Capital VIII, LLC
SEC ↗
5.60%
Averill Master Fund, Ltd.
Averill Master Fund, Ltd.
SEC ↗

Biohaven Executives and Management Board

13 members · avg. age 60 · 23 % women

VC

Dr. Vlad Coric (51)

Chairman of the Board, Chief Executive Officer · since 2015

10.92 M USD

Management

MB

Mr. Matthew Buten (61)

Chief Financial Officer

5.32 M USD
WJ

Mr. William Jones (58)

Chief Commercial Officer, Migraine and Common Diseases

4.69 M USD
ES

Dr. Elyse Stock (64)

Chief Medical Officer

3.88 M USD
KG

Ms. Kimberly Gentile (56)

Senior Vice President - Clinical Operations

3.76 M USD
CC

Dr. Charles Conway (60)

Chief Scientific Officer

2.79 M USD
JT

Mr. John Tilton (54)

Chief Commercial Officer, Rare and Orphan Diseases

1.53 M USD

Board of Directors

RH

Mr. Robert Hugin (67)

Independent Director

990,020.00 USD
MH

Mr. Michael Heffernan (57)

Lead Independent Director

987,799.00 USD
KM

Mr. Kishen Mehta (36)

Director

741,908.00 USD
JG

Ms. Julia Gregory (69)

Independent Director

560,063.00 USD
JC

Mr. John Childs (80)

Independent Director

560,013.00 USD
GB

Dr. Gregory Bailey (66)

Independent Director

541,826.00 USD

Frequently asked questions about Biohaven

Analysts currently set an average price target of 21.22 USD for the Biohaven stock (median: 15.30 USD), implying +57.2 % versus the latest price. The consensus is based on 23 analyst ratings.

Biohaven Analyst Price Targets 2026

23 analysts currently rate the Biohaven stock: 17 recommend buying, 6 holding and 0 selling. For 2026, analysts expect Biohaven to generate revenue of 2.45 M USD and earnings per share of -2.27 USD.

Biohaven Analyst Price Targets 2026

Converted at the current exchange rate, the Biohaven share trades at 11.73 EUR (13.50 USD).

The Biohaven share (BHVN) is listed on 2 stock exchanges, including: NYSE (BHVN), Frankfurt (2VN.F).

No history available for Biohaven.

The expected revenue of Biohaven is 2.45 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Biohaven is -272.77 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Biohaven is currently -5.95. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Biohaven stock.

The price-to-sales ratio (P/S) of Biohaven is currently 661.91. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Biohaven stock.

The Eulerpool Quality Score for Biohaven is 2/10.

The ISIN of Biohaven is VGG1110E1079. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Biohaven is A2DQ7W. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Biohaven is BHVN. The ticker symbol is used to trade Biohaven shares on the stock exchange.

Biohaven paid dividends every year for the past 0 years.

Biohaven is assigned to the 'Health' sector.

The dividends of Biohaven are distributed in USD.

All fundamentals and in-depth analysis of Biohaven

Our stock analysis for Biohaven stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biohaven. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Biohaven Stock
Biohaven Revenue→
Biohaven Stock
Biohaven Net Income→
Biohaven Stock
Biohaven P/E→
Biohaven Stock
Biohaven P/S→
Biohaven Stock
Biohaven EBIT→
Biohaven Stock
Biohaven Dividend→
Biohaven Stock
Biohaven Directors Dealings→
Biohaven Stock
Biohaven Stocks→
Biohaven Stock
Biohaven Market capitalization→
Biohaven Stock
Biohaven Debt→
Biohaven Stock
Biohaven Liabilities→
Biohaven Stock
Biohaven Equity→
Biohaven Stock
Biohaven AAQS→
Biohaven Stock
Biohaven Employees→
Biohaven Stock
Biohaven ROE→
Biohaven Stock
Biohaven ROA→
Biohaven Stock
Biohaven ROCE→
Biohaven Stock
Biohaven News→
Biohaven Stock
Biohaven Analyst Price Targets→

Health Stocks

Biohit OyjBiogend Therapeutics CoBioInfra CoBiogenBioInvent InternationalBiogaiaBioLASCO Taiwan CoBiofronteraBiolife SciencesBiofronteraBioLife SolutionsBiofil Chemicals and PharmaceuticalsAll Stocks A–Z →